دورية أكاديمية
Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905)
| العنوان: | Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905) |
|---|---|
| المؤلفون: | Kim, H. R., Jung, K. H., Im, S.-A., Im, Y.-H., Kang, S. Y., Park, K. H., Lee, S., Kim, S.-B., Lee, K.-H., Ahn, J. S., Kim, S. I., Sohn, J. H. |
| بيانات النشر: | Oxford University Press |
| سنة النشر: | 2013 |
| المجموعة: | HighWire Press (Stanford University) |
| مصطلحات موضوعية: | breast cancer |
| الوصف: | Background This phase II neoadjuvant trial evaluated bevacizumab–docetaxel and carboplatin in triple-negative breast cancer. Patients and methods Women with hormone receptor- and human epidermal growth factor receptor 2 (HER2)-negative, stage II/III breast cancer received six cycles of 75 mg/m2 docetaxel, carboplatin (AUC = 5) and 15 mg/kg bevacizumab every 21 days. The primary end point was pathological complete response (pCR) in breasts and axillary lymph nodes (ALN). Results Forty-five patients were recruited from the Korean Cancer Study Group. The median age was 45 (range 30–72) years. ALNs were positive in 80% of patients ( n = 36) at diagnosis. Overall, 98% of patients ( n = 44) completed therapy and underwent surgery. The pCR rate was 42% ( n = 19); clinical response rate 96% ( n = 43); complete 13% ( n = 6); partial 82% ( n = 37); stable disease 2% ( n = 1). Breast-conserving surgery was undertaken in 78% of patients ( n = 35). Most frequent grade 3/4 adverse events were neutropenia (84%, n = 38) and febrile neutropenia (9%, n = 4). One patient experienced delayed wound healing after surgery. Conclusions Neoadjuvant bevacizumab, docetaxel and carboplatin resulted in an encouraging pCR rate and negligible wound healing problems after surgery. |
| نوع الوثيقة: | text |
| وصف الملف: | text/html |
| اللغة: | English |
| العلاقة: | http://annonc.oxfordjournals.org/cgi/content/short/24/6/1485Test; http://dx.doi.org/10.1093/annonc/mds658Test |
| DOI: | 10.1093/annonc/mds658 |
| الإتاحة: | https://doi.org/10.1093/annonc/mds658Test http://annonc.oxfordjournals.org/cgi/content/short/24/6/1485Test |
| حقوق: | Copyright (C) 2013, European Society for Medical Oncology |
| رقم الانضمام: | edsbas.B6E65C96 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/annonc/mds658 |
|---|